Literature DB >> 3612870

Ten years of experience with the operative management of tibial shaft fractures.

P Rommens, K P Schmit-Neuerburg.   

Abstract

Two hundred ninety-three consecutive fresh tibial shaft fractures in 276 patients were treated operatively in a 10-year period. Eight patients required amputations. The early and late complications in both closed and open tibial shaft fractures are separately described and discussed. More than 90% of the closed fractures needed a normal healing time; osteitis developed in 2.5%. Eighty-eight per cent of the closed fractures had an excellent or acceptable end result. In the open fractures delayed union occurred in 9.0% and nonunion in 6.8%. Osteitis developed in 8.35%. Seventy-five per cent of open fractures and an excellent or good end result; one fourth had an acceptable or poor end result. In the series discussed there was a high incidence of direct trauma with soft-tissue injury in both closed and open tibial shaft fractures. There was a positive relationship between the degree of soft-tissue damage of the fractured lower leg at admission and the frequency of early postoperative problems. The frequency of late complications was more dependent on the fracture form and the method of the first operative stabilization.

Entities:  

Mesh:

Year:  1987        PMID: 3612870     DOI: 10.1097/00005373-198708000-00012

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  3 in total

1.  Quantitative early phase scintigraphy in the prediction of healing of tibial fractures.

Authors:  A L Wallace; R K Strachan; A Blane; J J Best; S P Hughes
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

2.  Patellar tendon bearing plaster casts in fractures of the tibia.

Authors:  S Ahmad; M K Mam; T S Sethi
Journal:  Int Orthop       Date:  1989       Impact factor: 3.075

3.  Interlocking intramedullary nailing for the treatment of tibial fractures.

Authors:  J O'Beirne; P Seigne; J P McElwain
Journal:  Ir J Med Sci       Date:  1992-01       Impact factor: 1.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.